Compare Bank of Montreal (BMO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs TG Therapeutics Inc — how do they compare? Bank of Montreal trades at $183.22 (market cap $126.83B), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: Bank of Montreal is far larger — about 16.6× TG Therapeutics Inc's market cap, and Bank of Montreal pays a 2.69% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BMO | TGTX | |
|---|---|---|
Market Cap | $126.83B | $7.64B |
Sector | Financials | Health |
52-Week High | $183.65 | $59.06 |
52-Week Low | $112.54 | $26.94 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $183.42, up 0.83% with a bullish technical signal. The company has delivered three consecutive earnings beats, with Q1 2026 EPS of $2.68 exceeding expectations. Revenue grew to $36.1B in 2025 with strong 24.12% net margins. Recent developments include the $1.44B Moneris sale and new ETN launches, positioning the bank for continued growth.
BMO presents a balanced investment case with solid fundamentals and positive earnings momentum offset by valuation concerns. The stock's 19.41 P/E ratio suggests fair valuation, while analyst sentiment remains divided with equal buy/hold ratings. Key risks include interest rate sensitivity and competitive pressures in the banking sector.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
